Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2021

View Archived Issues

aTyr Pharma describes monoclonal antibodies targeting neuropilin-2

Canopy Growth Corp. describes new cannabinoid CB1/CB2 receptor modulators

MAPK 8 inhibitors patented by Wuhan LL Science and Technology Development

Shanghai De Novo Pharmatech discloses G12C mutant GTPase KRAS inhibitors

Shanghai Newsky Biotechnology presents new PLA2G7 inhibitors

Fulcrum Therapeutics' FTX-6058 could be a disease-modifying treatment for sickle cell disease

Novel antibody-drug conjugate OBI-998 targets SSEA-4 for cancer therapy

CXCL17 protein expression is associated with tumor aggressiveness in cSCC

TST-005, a bifunctional fusion protein with promising antitumor activity in preclinical models

Phase IIb data for R-21 malaria vaccine adjuvanted with Matrix-M

Collaboration promotes new antimalarial drug development

FDA grants accelerated approval to Zynlonta for relapsed or refractory large B-cell lymphoma

Merck KGaA presents c-KIT inhibitors with strong antitumor activity in GIST

Phase III MELODY study of nirsevimab to prevent RSV infection in infants meets primary endpoint

Zyesami and Veklury studied within new ACTIV-3 Critical Care study for severe COVID-19

Neurodevelopmental and biomarker data for RGX-121 in a phase I/II study for severe MPS II

PHI-101 studied in phase I trial for relapsed or refractory AML

Vivet opens enrollment in phase I/II study of VTX-801 gene therapy for Wilson's disease

Phase II trial evaluates ALX-148 with pembrolizumab for advanced HNSCC

New phase I/II trial evaluates OBI-3424 for relapsed or refractory T-ALL and T-LBL

Immunome reports preclinical data on SARS-CoV-2 antibody cocktail IMM-BCP-01

Bayer initiates first-in-human study of BAY-2666605 in metastatic melanoma and advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...